Breaking News
March 23, 2019 - The Current issue of “The view from here” is concerned with Cancer
March 23, 2019 - Mouse model validates how ‘good’ and ‘bad’ bacteria affect acne
March 23, 2019 - Individual amygdala neurons respond to touch, imagery and sounds
March 23, 2019 - Combination of two topical creams can prevent cancer
March 23, 2019 - Study suggests depression screening when assessing African-Americans for schizophrenia
March 23, 2019 - New electronic support system for choosing drug treatment based on patient’s genotype
March 23, 2019 - First-of-its-kind study provides pregnancy statistics of imprisoned U.S. women
March 23, 2019 - Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
March 23, 2019 - Laparoscopy: MedlinePlus Lab Test Information
March 23, 2019 - Shellfish allergies: can they be treated?
March 23, 2019 - Toilet seat heart monitoring system
March 23, 2019 - Researchers identify way to improve common treatment for PTSD
March 23, 2019 - High potency cannabis use linked to psychosis finds study
March 23, 2019 - Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
March 23, 2019 - Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
March 23, 2019 - Scientists grow most sophisticated brain organoid to date
March 23, 2019 - ADHD drug raising risk of psychosis
March 22, 2019 - FDA approves brexanolone, first drug developed to treat postpartum depression
March 22, 2019 - Gruesome cat and dog experiments by the USDA exposed
March 22, 2019 - Ball pits used in children’s physical therapy may contribute to germ transmission
March 22, 2019 - Long-term use of inexpensive weight-loss drug may be safe and effective
March 22, 2019 - FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
March 22, 2019 - Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
March 22, 2019 - Finding the right exercise, diet aids for HIV patients
March 22, 2019 - Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
March 22, 2019 - Researchers develop new tool for imaging large groups of neurons in living animals
March 22, 2019 - Certain bacteria and immune factors in vagina may cause or protect against preterm birth
March 22, 2019 - Novel breath test could pave new way to non-invasively measure gut health
March 22, 2019 - Pharmaceutical and personal care products may result in new contaminants in waterways
March 22, 2019 - ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
March 22, 2019 - Wiedemann-Rautenstrauch syndrome – Genetics Home Reference
March 22, 2019 - Health insurance is not assurance of healthcare
March 22, 2019 - Supporting “curiosity-driven research” at the Discovery Innovation Awards
March 22, 2019 - Must-Reads Of The Week (Some Flying Below The Radar)
March 22, 2019 - Newly engineered nanoscale protein micelles can be tracked by MRI
March 22, 2019 - New model more effective in predicting risk of opioid overdose than traditional models
March 22, 2019 - Mayo Clinic study identifies potential new drug therapy for liver diseases
March 22, 2019 - Pitt engineers win $550,000 NSF CAREER award to develop new intervention for people with ASD
March 22, 2019 - Early discharge does not increase readmission risk for patients after lung surgery
March 22, 2019 - Creating diverse pool of trained scientists to address Alzheimer’s research needs
March 22, 2019 - Surprising discovery offers clues to limit graft-vs.-host disease
March 22, 2019 - Study shows ACA’s positive impact on healthcare affordability and access for women
March 22, 2019 - Study provides new pathway for controlling inflammation
March 22, 2019 - New combination treatment shows promise for common brain tumor in children
March 22, 2019 - Virginia Tech Helmet Lab releases first youth-specific football helmet ratings
March 22, 2019 - New algae-based treatment could reduce need for limb amputation
March 22, 2019 - Stroke risk reduces in both black and white older Medicare beneficiaries, study reports
March 22, 2019 - City of Hope exhibits current studies and data on cancer therapies at AACR
March 22, 2019 - New study identifies CD40 molecule as key entry point for dangerous bacteria
March 22, 2019 - Health Tip: Six Steps to a Healthier Life
March 22, 2019 - even a little activity helps you live longer
March 22, 2019 - Many individuals recovering from addiction continue to suffer from chronic physical disease
March 22, 2019 - New drugs on PBS for Parkinson’s, MND and Cutaneous T cell lymphoma
March 22, 2019 - Saving energy also saves lives, UW-Madison study says
March 22, 2019 - Former inmates who receive social support have better mental health, study finds
March 22, 2019 - Nanofibrous membrane could enhance periodontal tissue regeneration
March 22, 2019 - Anti-vaxxer Italian leader down with chickenpox
March 22, 2019 - Servier collaborates with Harvard researchers to fight metabolic diseases
March 22, 2019 - National Eating Disorders Association
March 22, 2019 - Pumping up red blood cell production
March 22, 2019 - Excessive phosphate fertilizer may hurt plants by altering microbial composition in soil
March 22, 2019 - Medical marijuana laws could be improving older Americans’ health, study suggests
March 22, 2019 - Study indicates the benefits of stopping aspirin in heart attack patients
March 22, 2019 - Deep brain stimulation offers significant relief for patients with treatment-resistant depression
March 22, 2019 - Mental health problems in young adults on the rise
March 22, 2019 - Innovative membrane offers a viable solution for periodontitis
March 22, 2019 - The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
March 22, 2019 - insulin therapy: MedlinePlus Medical Encyclopedia
March 22, 2019 - Guidelines on the use of genetic testing in psychiatry
March 22, 2019 - Aspiring Doctors Seek Advanced Training In Addiction Medicine
March 22, 2019 - A change in focus could enable the development of new treatments for Alzheimer’s disease
March 22, 2019 - A new way to visualize the immune cell “landscape” of bowel cancer tumors
March 22, 2019 - Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia
March 22, 2019 - Ludwig scientists to share advances in cancer research at AACR Annual Meeting 2019
March 22, 2019 - Less invasive valve replacement can be safe and effective alternative for healthier patients
March 22, 2019 - Aphasia research reveals new, complex interactions between thought and language
March 22, 2019 - Artificial neural networks can predict how different areas in the brain respond to words
March 22, 2019 - Age-related changes to gut microbiome have adverse impact on vascular health, study shows
March 22, 2019 - Study provides new insight into blood cell and immune cell production
March 22, 2019 - Isolated seniors chat online to prevent cognitive decline
SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids

SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids

image_pdfDownload PDFimage_print

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or “chemo brain,” symptoms and unwanted side effects of opioids.

Salvemini, who is professor of pharmacology and physiology at Saint Louis University, has spent her career attempting to understand how pain happens in the body, including chronic pain, cancer pain and chemotherapy-induced pain. She studies pain pathways, the series of interactions between molecular-level components, to understand how pain occurs in order to develop new treatments.

With these awards, Salvemini will expand her work to seek answers to urgent questions surrounding pain and cancer drugs.

Chemotherapy-induced cognitive impairment, or “chemo-brain”

A $2,814,902 grant will allow Salvemini to study a common, debilitating side-effect of chemotherapy called chemotherapy-induced cognitive impairment. She is joined by co-investigators Timothy Doyle, Ph.D., Grant R. Kolar, Ph.D., and Susan Farr, Ph.D. from SLU as well as Jacoba (Cobi) Heijnen, Ph.D., and her team at MD Anderson Cancer Center.

Advances in cancer treatment have led to a sharp increase in the number of cancer survivors, reaching nearly 15 million people in the United States alone. However, in many cases, cancer treatment is associated with severe neurotoxic side effects that not only can disrupt social, educational and occupational functioning, but also decrease survival by interfering with adherence to medication and healthy behavior.

Chemotherapy-induced cognitive impairment (CICI), sometimes called “chemo-brain,” is a major neurotoxic side effect of platinum-based (such as cisplatin) and anthracyclins (such as doxorubicin) chemotherapy drugs that are widely used as part of standard treatment for numerous cancers, including head and neck, testicular, colon, breast, ovarian and non-small cell lung cancers.

CICI is characterized by subtle to moderate cognitive deficits that include decreases in processing speed, memory, executive functioning and attention – side effects which can dramatically impact quality of life for patients, with symptoms persisting well after exposure. With nearly 40 percent of adults projected to be diagnosed with cancer in their lifetime and with CICI rates that are greater 50 percent in cancer patients and survivors, CICI represents a growing public health concern.

Little is known about the mechanisms underlying CICI, and there are no FDA-approved drugs to prevent or cure the condition.

“It is imperative that we understand the underlying causes of this serious adverse drug reaction and identify novel therapeutic approaches with the potential for rapid translation to the clinic,” Salvemini said.

In previous work, Salvemini and her team found that chemotherapy dysregulates endogenous adenosine signaling at one of its receptors, A3AR, leading to neuroinflammatory processes and mitochondrial dysfunction in the central nervous system that contribute to the development and continuation of cognitive impairment.

This grant will explore the use of highly selective A3AR agonists – chemicals that activate the nuclear receptor – as a therapeutic approach to mitigate chemo-brain, providing new molecular insights that will advance our understanding of how chemo-brain occurs.

The researchers also hope their study will show whether CICI can be reversed or turned down once symptoms have appeared by turning on the A3AR receptor. This finding would offer hope that cognitive function could be restored in those cancer survivors who have been already developed CICI.

The team expects that this work will lead to expedited “proof-of-concept” studies, opening the door to a new translational effort in the treatment of chemo-brain to find solutions for this highly unmet medical need.

“We hope that the combination of an A3AR agonist with chemo will prevent dose limiting toxicities, therefore enabling the patient to undergo their full cycle of chemo,” Salvemini said. “More excitingly, we hope that we can reverse the toxicity that has already established thus making a big difference to the quality of life of patients who are cancer free but who are still affected by CICI.

“Imagine patients being able to lead normal lives, putting a shirt or a sock on without feeling pain or the ability to perform a simple daily task because their cognitive impairment is improved or at least not worsened. This is our mission: to make an impact on human suffering. I have dedicated over 25 years to this and I am more motivated than ever.

“I am so grateful to my collaborators and team for their dedication to these efforts.”

Opioids and Pain, Tolerance and Dependence

A $1,722,666 NIH grant will allow Salvemini to study another alarming problem: opioid pain killers that are capable of quelling terrible pain also carry debilitating side effects and significant risk of addiction. She is joined by co-investigators who include Timothy Doyle, Ph.D. and Grant R. Kolar, Ph.D., from SLU as well as Todd Vanderah, Ph.D., and his team at the University of Arizona.

This pain problem sets up a discouraging dilemma for patients and doctors. Opioid pain killers, like hydrocodone and morphine, can ease unbearable pain for those who are suffering. The price, however, can be side effects like nausea, vomiting, drowsiness or sedation, and psychological effects like euphoria, hallucinations or delirium. They also can lead to addiction and cause withdrawal symptoms once halted.

As she searches for new ways to mitigate the side effects of these drugs while preserving their pain killing ability, Salvemini will build on previous work that studied alterations in sphingolipid signaling in the brain.

Salvemini found that these alterations cause the development of several opioid side effects, including pain caused by the chronic use of opioids, called opioid-induced hyperalgesia (OIH), and tolerance, which happens when opioids lose their effects over time, called antinociceptive tolerance, which can lead to increased doses which in turn can contribute to dependence.

Salvemini and her team have identified the molecular cause that drives these unwanted opioid effects. With this grant, they will explore the mechanisms at the cellular and molecular levels that cause OIH, tolerance and dependence.

Salvemini hopes this work will lead to a drug that could be taken together with opioids.

“The idea is to combine a drug that blocks sphingolipid signaling with opioids in order to preserve opioids’ pain-killing properties, but minus their side effects,” Salvemini said.

Source:

https://www.slu.edu/news/2018/october/side-effects-of-cancer-and-pain-medications.php

Tagged with:

About author

Related Articles